Nycomed's profits up by 58% in first quarter, but OTC business suffers
This article was originally published in Scrip
Executive Summary
Nycomed's profits rose by 58% to €88 million in the first quarter and it posted €840 million in net sales, up by 1% (+3.8% excluding currency effects) compared with the same period last year. However, the current global downturn affected the company's OTC business, with total OTC sales falling by 9% to €107 million.